iTeos Therapeutics (ITOS) News Today $10.00 0.00 (0.00%) As of 11:27 AM Eastern Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ITOS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period iTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Michel Detheux Sells 43,883 SharesJune 12 at 8:50 AM | insidertrades.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Sells $439,707.66 in StockiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,883 shares of the business's stock in a transaction on Tuesday, June 10th. The stock was sold at an average price of $10.02, for a total transaction of $439,707.66. Following the completion of the sale, the chief executive officer now directly owns 153,903 shares of the company's stock, valued at approximately $1,542,108.06. The trade was a 22.19% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.June 11 at 11:21 PM | marketbeat.comMichel Detheux Sells 43,882 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,882 shares of the firm's stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $10.03, for a total transaction of $440,136.46. Following the completion of the transaction, the chief executive officer now directly owns 153,903 shares in the company, valued at $1,543,647.09. This represents a 22.19% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.June 11 at 11:21 PM | marketbeat.comiTeos Therapeutics Inc.June 11 at 8:00 PM | barrons.comInsider Selling: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells 38,228 Shares of StockJune 9 at 4:33 AM | americanbankingnews.comiTeos Therapeutics validates InvestingPro’s Fair Value analysis with 70% returnJune 9 at 1:46 AM | uk.investing.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Receives Consensus Recommendation of "Hold" from BrokeragesShares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) have been assigned a consensus rating of "Hold" from the seven ratings firms that are covering the stock, Marketbeat Ratings reports. Six equities research analysts have rated the stock with a hold rating and one has assigned a buJune 8, 2025 | marketbeat.comInsider Selling: iTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells 38,227 Shares of StockJune 7, 2025 | insidertrades.comDavid Hallal Sells 38,227 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) Director David Hallal sold 38,227 shares of the business's stock in a transaction dated Thursday, June 5th. The shares were sold at an average price of $10.15, for a total transaction of $388,004.05. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.June 6, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Director Sells $391,454.72 in StockiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) Director David Hallal sold 38,228 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The stock was sold at an average price of $10.24, for a total transaction of $391,454.72. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink.June 6, 2025 | marketbeat.comMichel Detheux Sells 43,883 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) StockiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,883 shares of the company's stock in a transaction on Wednesday, June 4th. The stock was sold at an average price of $10.10, for a total transaction of $443,218.30. Following the completion of the sale, the chief executive officer now owns 135,903 shares of the company's stock, valued at approximately $1,372,620.30. The trade was a 24.41% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.June 6, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) CEO Sells $448,035.22 in StockiTeos Therapeutics, Inc. (NASDAQ:ITOS - Get Free Report) CEO Michel Detheux sold 43,882 shares of the stock in a transaction on Friday, June 6th. The shares were sold at an average price of $10.21, for a total value of $448,035.22. Following the completion of the sale, the chief executive officer now owns 135,903 shares of the company's stock, valued at $1,387,569.63. The trade was a 24.41% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.June 6, 2025 | marketbeat.comStocks With Rising Relative Strength: iTeos TherapeuticsJune 6, 2025 | msn.comNuveen Asset Management LLC Trims Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Nuveen Asset Management LLC decreased its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 61.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 60,401 shares of the company'sJune 6, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Shares Bought by Public Employees Retirement System of OhioPublic Employees Retirement System of Ohio lifted its holdings in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 192.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 84,220June 5, 2025 | marketbeat.comResearch Analysts Offer Predictions for ITOS Q2 EarningsJune 2, 2025 | americanbankingnews.comQ2 EPS Forecast for iTeos Therapeutics Decreased by AnalystiTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Equities researchers at Leerink Partnrs dropped their Q2 2025 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a research report issued to clients and investors on Wednesday, May 28th. Leerink Partnrs analyst D. GrayboscJune 2, 2025 | marketbeat.comMillennium Management LLC Has $3.16 Million Stock Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Millennium Management LLC grew its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 1,008.8% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 411,072 shares of the company's stock after purchaJune 1, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Position Increased by Ameriprise Financial Inc.Ameriprise Financial Inc. increased its position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 233.6% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 205,188 sharesJune 1, 2025 | marketbeat.comWedbush Lowers Earnings Estimates for iTeos TherapeuticsiTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Analysts at Wedbush dropped their Q2 2025 earnings per share estimates for shares of iTeos Therapeutics in a research note issued to investors on Wednesday, May 28th. Wedbush analyst D. Nierengarten now expects that the company will post earnMay 31, 2025 | marketbeat.comiTeos Therapeutics Announces Intent to Wind Down Operations and Explore Asset Sales to Maximize Shareholder ValueMay 30, 2025 | nasdaq.comiTeos Therapeutics' (ITOS) "Equal Weight" Rating Reaffirmed at Wells Fargo & CompanyWells Fargo & Company reaffirmed an "equal weight" rating and issued a $12.00 price target (down previously from $13.00) on shares of iTeos Therapeutics in a research note on Wednesday.May 29, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Stock Rating Lowered by WedbushWedbush cut shares of iTeos Therapeutics from an "outperform" rating to a "neutral" rating and set a $12.00 price target on the stock. in a report on Wednesday.May 29, 2025 | marketbeat.comWedbush Downgrades iTeos Therapeutics (ITOS)May 29, 2025 | msn.comiTeos Therapeutics stock surges on wind-down newsMay 28, 2025 | za.investing.comiTeos Therapeutics Stock Jumps Following Operational Closure AnnouncementMay 28, 2025 | msn.comiTeos Therapeutics To Wind Down Operations, Explores Asset Sale: Retail Believes It’s ‘Worth More Selling It Off’May 28, 2025 | msn.comiTeos Therapeutics Inc.: iTeos Therapeutics Announces Its Intention to Wind Down OperationsMay 28, 2025 | finanznachrichten.deITeos Therapeutics Shares Surge on Wind Down of OperationsMay 28, 2025 | marketwatch.comiTeos plans to shut down operations after cancer therapy setbackMay 28, 2025 | reuters.comiTeos surges on plans to end operationsMay 28, 2025 | seekingalpha.comiTeos Therapeutics Announces Its Intention to Wind Down OperationsMay 28, 2025 | globenewswire.comD. E. Shaw & Co. Inc. Cuts Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)D. E. Shaw & Co. Inc. cut its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 55.0% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 56,534 shares of the company's stock after selling 69,227 shares during the period. D. E.May 28, 2025 | marketbeat.com60,079 Shares in iTeos Therapeutics, Inc. (NASDAQ:ITOS) Purchased by BNP Paribas Financial MarketsBNP Paribas Financial Markets purchased a new position in shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor purchased 60,079 shares of the company's stock, valued at appMay 26, 2025 | marketbeat.comVestal Point Capital LP Sells 125,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)Vestal Point Capital LP lessened its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 12.2% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 900,000 shares of the company's stock after selling 125,000 shares duMay 21, 2025 | marketbeat.comStonepine Capital Management LLC Buys 80,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)Stonepine Capital Management LLC grew its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 266.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 110,000 shares of the company's stock after acquiringMay 20, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Stock Position Cut by Tang Capital Management LLCTang Capital Management LLC lessened its stake in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 90.8% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 221,716 shares of the company's stock after selMay 20, 2025 | marketbeat.comQ2 Earnings Forecast for ITOS Issued By Leerink PartnrsiTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) - Stock analysts at Leerink Partnrs issued their Q2 2025 earnings per share (EPS) estimates for shares of iTeos Therapeutics in a research report issued to clients and investors on Wednesday, May 14th. Leerink Partnrs analyst D. Graybosch expecMay 20, 2025 | marketbeat.comCubist Systematic Strategies LLC Decreases Position in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Cubist Systematic Strategies LLC cut its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 53.0% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 62,178 shares of the company's stock after selling 70,186 shares during the period. Cubist SystMay 19, 2025 | marketbeat.comiTeos Therapeutics (NASDAQ:ITOS) Stock Rating Lowered by Leerink PartnrsLeerink Partnrs lowered shares of iTeos Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Wednesday.May 17, 2025 | marketbeat.comLeerink Partners Reiterates "Market Perform" Rating for iTeos Therapeutics (NASDAQ:ITOS)Leerink Partners restated a "market perform" rating and issued a $9.00 price objective (down from $47.00) on shares of iTeos Therapeutics in a report on Wednesday.May 16, 2025 | marketbeat.comiTeos Therapeutics, Inc. (NASDAQ:ITOS) Major Shareholder Bioventures 2018 L.P. Mpm Sells 630,191 SharesMay 16, 2025 | insidertrades.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 59,649 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 90.5% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 125,589 shares of the compMay 16, 2025 | marketbeat.comJacobs Levy Equity Management Inc. Grows Stock Holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS)Jacobs Levy Equity Management Inc. grew its holdings in iTeos Therapeutics, Inc. (NASDAQ:ITOS - Free Report) by 347.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 922,134 shares of the company's stock after acquiringMay 16, 2025 | marketbeat.comLeerink Partners Downgrades iTeos Therapeutics (ITOS)May 15, 2025 | msn.comiTeos Therapeutics: End To Belrestotug Program Leads To A Hold RatingMay 15, 2025 | seekingalpha.comITeos Therapeutics Shares Gain as Company Seeks Strategic AlternativesMay 14, 2025 | marketwatch.comiTeos stock rises despite clinical trial setbackMay 14, 2025 | investing.comiTeos Therapeutics: TIGIT Falls, And A Zombie Rises?May 14, 2025 | seekingalpha.comiTeos Reports Topline Interim Results from GALAXIES Lung-201 Study of Belrestotug + Dostarlimab in First-Line, PD-L1 High Non-Small Cell Lung Cancer PatientsMay 13, 2025 | globenewswire.com Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address ITOS Media Mentions By Week ITOS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ITOS News Sentiment▼0.150.87▲Average Medical News Sentiment ITOS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ITOS Articles This Week▼233▲ITOS Articles Average Week Get iTeos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ITOS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies JANX News Today MESO News Today EVO News Today SPRY News Today OCUL News Today VERA News Today ANIP News Today TVTX News Today BGM News Today AMPH News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ITOS) was last updated on 6/12/2025 by MarketBeat.com Staff From Our PartnersTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBanks aren’t ready for this altcoin—are you?While everyone's distracted by Bitcoin's moves, a stealth revolution is underway. One altcoin is quietly po...Crypto 101 Media | Sponsored[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding iTeos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share iTeos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ITOS Stock Free ITOS Stock Alerts